Merck has been quietly making moves worldwide to position molnupiravir as the standard early-onset, orally-administered antiviral treatment for COVID-19. TrialSite has reported that Merck’s teams are crisscrossing the globe, inking deals with governments and generic drug companies. In Vietnam, the drug is even being administered as part of a home care program in Ho Chi Minh City, similar to how ivermectin has been used in Uttar Pradesh, India, and other places. Controversially this is outside of a controlled trial. Now the Egypt Independent reports, “Egypt’s Ministry of Health and Population has started working to provide new drugs that will change coronavirus resistance by reducing the viral load.” In a statement on Friday, the ministry said that the “molnupiravir” drug reduces the viral load of the disease and that Egypt is participating in two studies by the company producing the drug.
Egypt’s existing national COVID-19 protocol includes Hydroxychloroquine, Budesonide, and several other treatments depending on the stage of infection. By last year, an Egyptian pharmaceutical company, Eva Pharma, was also producing both remdesivir and favipiravir.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).